CG0070 + Pembrolizumab...Not even close to TLT-Ruvidar.I am still on my holiday break, but could not resist to give my point of view on CG0070+Pembrolizumab.
It never cease to amaze me how some posters do not take the time to research the treatment that they say will compete with TLT-Ruvidar.
In this link...
https://mayo.edu/research/clinical-trials/cls-20508002#eligibility In this link under "Participation Eligibility", there is a small red box that say "show more eligibility criteria".
If you look at the "exclusion criteria".
You come to the conclusion that except for having BCG resistant bladder cancer, the patient in order to receive CG0070+Pembrolizumab has to be almost in perfect health.
In short ...
If TLT-Ruvidar was treating the same kind of patients as CG0070+Pembrolizumab(with the same exclusion criteria), TLT-Ruvidar could easily have a 80-90% CR over 12 months.You have to remember that TLT-Ruvidar treat all patients without restrictions and as a bonus has side effects.
I am going back on my holiday break(will be back in 2024 unless ???), for the posters that bring on these kind of false competitors to TLT-Ruvidar, please take the time to google it first.